
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …

The emerging field of RNA interference – also known as ‘gene silencing’ – is one of the most promising in …
A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …
Novartis has joined the race to develop a ‘gene silencing’ treatment by signing a new deal with siRNA specialist Quark …
Jorg Kaufmann has been made vice president of research at UK biotech company Silence Therapeutics. He previously served as senior …
US researchers have shown that a targeted nanoparticle can penetrate cancer cells in order to deliver small interfering RNAs (siRNAs), …
Coronado Biosciences’ cancer treatment effective in animal modelsCoronado Biosciences has reported that the Bcl-2 inhibitor, apogossypol, effectively killed a variety …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

